Comparison of ATA and Updated ACOG Guidelines for Thyroid Disease in Pregnancy. Russian translation
https://doi.org/10.14341/ket12556
Abstract
Thyroid dysfunction is relatively common in pregnancy. The American Thyroid Association (ATA) published its most recent guidelines regarding the management of thyroid disorders in pregnancy in 2017. The American College of Obstetricians and Gynecologists (ACOG) has recently published an updated practice bulletin for thyroid disease in pregnancy that supersedes its previous guidance published in 2015. A comparison of the similarities and differences between the clinical guidelines from the ATA and ACOG can serve to highlight areas of uncertainty where additional studies are needed and may also demonstrate areas where endocrinologists and obstetricians may elect differing approaches to clinical care. The ACOG and ATA guidelines recommend similar approaches to the interpretation of thyroid function testing during gestation and to the management of thyroid cancer, thyroid nodules, gestational thyrotoxicosis, and postpartum thyroiditis Both strongly recommend levothyroxine (L-T4) treatment for overtly hypothyroid pregnant women, and both recommend against the use of T3-containing thyroid hormone preparations when treating hypothyroidism in pregnancy.
About the Author
Elizabeth N. PearceIodine Global Network (IGN)
United States
MD, MSc, Professor of Medicine.
Boston
Competing Interests:
Not existing
References
1. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2020;27(3):315-389. doi: https://doi.org/10.1089/thy.2016.0457.
2. American College of Obstetricians and Gynecologists. Thyroid disease in pregnancy: ACOG practice bulletin, number 223. Obstet Gynecol. 2020;135(6):e261-e274. doi: https://doi.org/10.1097/AOG.0000000000003893.
3. American College of Obstetricians and Gynecologists. Practice bulletin no. 148: thyroid disease in pregnancy. Obstet Gynecol. 2020;125(4):996-1005. doi: https://doi.org/10.1097/01.AOG.0000462945.27539.93
4. Momotani N, Noh J, Oyanagi H, et al. Antithyroid drug therapy for Graves’ disease during pregnancy: Optimal regimen for fetal thyroid status. N Engl J Med. 1986;315(1):24-28. doi: https://doi.org/10.1056/NEJM198607033150104.
5. Abuid J, Larsen P. Triiodothyronine and thyroxine in hyperthyroidism: comparison of the acute changes during therapy with antithyroid agents. J Clin Invest. 1974;54(1):201-208. doi: https://doi.org/10.1172/JCI107744.
6. Lazarus JH, Bestwick JP, Channon S, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med. 2020;366(6):493-501. doi: https://doi.org/10.1056/NEJMoa1106104.
7. Casey BM, Thom EA, Peaceman AM, et al. Treatment of subclinical hypothyroidism or hypothyroxinemia in pregnancy. N Engl J Med. 2017;376(9):815–825. doi: https://doi.org/10.1056/NEJMoa1606205.
8. Dhillon-Smith RK, Middleton LJ, Sunner KK, et al. Levothyroxine in women with thyroid peroxidase antibodies before conception. N Engl J Med. 2019;380(14):1316–1325. doi: https://doi.org/10.1056/NEJMoa1812537.
Review
For citations:
Pearce E.N. Comparison of ATA and Updated ACOG Guidelines for Thyroid Disease in Pregnancy. Russian translation. Clinical and experimental thyroidology. 2020;16(3):12-15. (In Russ.) https://doi.org/10.14341/ket12556

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).